Print

UCLA MIG-003

A Phase I Double Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of the Aventis Pasteur ALVAC-HIV (vCP205) Administered to the Groin Area Versus the Deltoid Area

Trial Details:

I Completed
University of California, Los Angeles October 28, 2003
ALVAC-HIV MN120TMG strain (vCP205) Pox Env, gag pol B
ALVAC-HIV MN120TMG strain (vCP205) Viral Vector - Pox
USA 18
NCT00076817
http://clinicaltrials.gov/ct/show/NCT00076817?order=10